Duesterdieck-Zellmer Katja F, Moneta Lindsey, Ott Jesse F, Larson Maureen K, Gorman Elena M, Hunter Barbara, Löhr Christiane V, Payton Mark E, Morré Jeffrey T, Maier Claudia S
Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
PeerJ. 2014 Sep 4;2:e534. doi: 10.7717/peerj.534. eCollection 2014.
To determine effects of intraarticularly administered tiludronate on articular cartilage in vivo, eight healthy horses were injected once with tiludronate (low dose tiludronate [LDT] 0.017 mg, n = 4; high dose tiludronate [HDT] 50 mg, n = 4) into one middle carpal joint and with saline into the contralateral joint. Arthrocentesis of both middle carpal joints was performed pre-treatment, and 10 min, 24 h, 48 h, 7 and 14 days after treatment. Synovial nucleated cell counts and total solids, tiludronate, sulfated glycosaminoglycan (sGAG), chondroitin sulfate 846 epitope (CS-846, a measure of aggrecan synthesis), and collagen type II cleavage neoepitope (C2C) concentrations were determined. Histologic analysis of joint tissues and sGAG quantitation in cartilage was performed at 14 days in HDT horses. Data were analyzed by repeated measures non-parametric ANOVA and Wilcoxon signed-rank test. High dose tiludronate administration produced synovial fluid tiludronate concentrations of 2,677,500 ng/mL, exceeding concentrations that were safe for cartilage in vitro, and LDT administration produced synovial fluid concentrations of 1,353 ng/mL, remaining below concentrations considered potentially detrimental to cartilage. With HDT, synovial fluid total solids concentration was higher at 24 h and 7 days and sGAG concentration was higher at 48 h, compared to control joints. Synovial fluid CS-846 concentration was increased over pre-treatment values in HDT control but not in HDT treated joints at 24 and 48 h. All joints (HDT and LDT control and treated) showed a temporary decrease in synovial fluid C2C concentration, compared to pre-treatment values. Histologic features of articular cartilage and synovial membrane did not differ between HDT treated and control joints. High dose tiludronate treatment caused a transient increase in synovial total solids and temporarily increased proteoglycan degradation in cartilage. Although clinical significance of these changes are questionable, as they did not result in articular cartilage damage, further investigation of the safety of intraarticular HDT in a larger number of horses is warranted.
为了确定关节内注射替鲁膦酸盐对体内关节软骨的影响,8匹健康马的一侧腕中关节注射一次替鲁膦酸盐(低剂量替鲁膦酸盐[LDT]0.017mg,n = 4;高剂量替鲁膦酸盐[HDT]50mg,n = 4),对侧关节注射生理盐水。在治疗前以及治疗后10分钟、24小时、48小时、7天和14天对双侧腕中关节进行关节穿刺。测定滑膜有核细胞计数、总固体、替鲁膦酸盐、硫酸化糖胺聚糖(sGAG)、硫酸软骨素846表位(CS - 846,一种聚集蛋白聚糖合成的指标)和II型胶原裂解新表位(C2C)浓度。在HDT组马匹中,于14天时对关节组织进行组织学分析并对软骨中的sGAG进行定量。数据采用重复测量非参数方差分析和Wilcoxon符号秩检验进行分析。高剂量替鲁膦酸盐给药后滑膜液中替鲁膦酸盐浓度达到2,677,500ng/mL,超过了体外对软骨安全的浓度,而LDT给药后滑膜液浓度为1,353ng/mL,仍低于被认为可能对软骨有害的浓度。与对照关节相比,HDT组在24小时和7天时滑膜液总固体浓度较高,在48小时时sGAG浓度较高。在HDT对照组中,滑膜液CS - 846浓度在24小时和48小时时高于治疗前值,但在HDT治疗关节中未升高。与治疗前值相比,所有关节(HDT和LDT对照组及治疗组)的滑膜液C2C浓度均出现暂时下降。HDT治疗关节和对照关节之间的关节软骨和滑膜组织学特征无差异。高剂量替鲁膦酸盐治疗导致滑膜总固体短暂增加,并使软骨中蛋白聚糖降解暂时增加。尽管这些变化的临床意义值得怀疑,因为它们未导致关节软骨损伤,但仍有必要对更多马匹进行关节内HDT安全性的进一步研究。